Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sintilimab Plus Bevacizumab in Patients With Recurrent/Persistent Ovarian Clear Cell Carcinoma

Trial Profile

Sintilimab Plus Bevacizumab in Patients With Recurrent/Persistent Ovarian Clear Cell Carcinoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Sintilimab (Primary)
  • Indications Carcinoma; Ovarian cancer
  • Focus Therapeutic Use
  • Acronyms INOVA
  • Most Recent Events

    • 07 May 2024 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified April 2022).
    • 13 Sep 2022 Results (n=23; Between April 8, 2021 and April 25, 2022 (data cutoff)) assessing the potential benefit of sintilimab plus bevacizumab combination therapy for recurrent/persistent ovarian clear cell carcinoma patients, presented at the 47th European Society for Medical Oncology Congress.
    • 18 Apr 2022 Planned End Date changed from 31 Dec 2023 to 30 Apr 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top